These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

329 related items for PubMed ID: 22472882

  • 1. PPARgamma inhibits hepatocellular carcinoma metastases in vitro and in mice.
    Shen B, Chu ES, Zhao G, Man K, Wu CW, Cheng JT, Li G, Nie Y, Lo CM, Teoh N, Farrell GC, Sung JJ, Yu J.
    Br J Cancer; 2012 Apr 24; 106(9):1486-94. PubMed ID: 22472882
    [Abstract] [Full Text] [Related]

  • 2. Inhibitory role of peroxisome proliferator-activated receptor gamma in hepatocarcinogenesis in mice and in vitro.
    Yu J, Shen B, Chu ES, Teoh N, Cheung KF, Wu CW, Wang S, Lam CN, Feng H, Zhao J, Cheng AS, To KF, Chan HL, Sung JJ.
    Hepatology; 2010 Jun 24; 51(6):2008-19. PubMed ID: 20512989
    [Abstract] [Full Text] [Related]

  • 3. PPARgamma activator rosiglitazone inhibits cell migration via upregulation of PTEN in human hepatocarcinoma cell line BEL-7404.
    Zhang W, Wu N, Li Z, Wang L, Jin J, Zha XL.
    Cancer Biol Ther; 2006 Aug 24; 5(8):1008-14. PubMed ID: 16775433
    [Abstract] [Full Text] [Related]

  • 4. Activation of peroxisome proliferator-activated receptor-γ (PPARγ) inhibits hepatoma cell growth via downregulation of SEPT2 expression.
    Cao LQ, Shao ZL, Liang HH, Zhang DW, Yang XW, Jiang XF, Xue P.
    Cancer Lett; 2015 Apr 01; 359(1):127-35. PubMed ID: 25592041
    [Abstract] [Full Text] [Related]

  • 5. A peroxisome proliferator-activated receptor gamma antagonist induces vimentin cleavage and inhibits invasion in high-grade hepatocellular carcinoma.
    Kim KR, Choi HN, Lee HJ, Baek HA, Park HS, Jang KY, Chung MJ, Moon WS.
    Oncol Rep; 2007 Oct 01; 18(4):825-32. PubMed ID: 17786342
    [Abstract] [Full Text] [Related]

  • 6. Rosiglitazone inhibits metastasis development of a murine mammary tumor cell line LMM3.
    Magenta G, Borenstein X, Rolando R, Jasnis MA.
    BMC Cancer; 2008 Feb 08; 8():47. PubMed ID: 18261208
    [Abstract] [Full Text] [Related]

  • 7. CITED2 is a novel direct effector of peroxisome proliferator-activated receptor γ in suppressing hepatocellular carcinoma cell growth.
    Cheung KF, Zhao J, Hao Y, Li X, Lowe AW, Cheng AS, Sung JJ, Yu J.
    Cancer; 2013 Mar 15; 119(6):1217-26. PubMed ID: 23212831
    [Abstract] [Full Text] [Related]

  • 8. Peroxisome proliferator-activated receptor gamma inhibition prevents adhesion to the extracellular matrix and induces anoikis in hepatocellular carcinoma cells.
    Schaefer KL, Wada K, Takahashi H, Matsuhashi N, Ohnishi S, Wolfe MM, Turner JR, Nakajima A, Borkan SC, Saubermann LJ.
    Cancer Res; 2005 Mar 15; 65(6):2251-9. PubMed ID: 15781638
    [Abstract] [Full Text] [Related]

  • 9. Hispidulin inhibits hepatocellular carcinoma growth and metastasis through AMPK and ERK signaling mediated activation of PPARγ.
    Han M, Gao H, Ju P, Gao MQ, Yuan YP, Chen XH, Liu KL, Han YT, Han ZW.
    Biomed Pharmacother; 2018 Jul 15; 103():272-283. PubMed ID: 29656183
    [Abstract] [Full Text] [Related]

  • 10. Rosiglitazone sensitizes hepatocellular carcinoma cell lines to 5-fluorouracil antitumor activity through activation of the PPARgamma signaling pathway.
    Cao LQ, Wang XL, Wang Q, Xue P, Jiao XY, Peng HP, Lu HW, Zheng Q, Chen XL, Huang XH, Fu XH, Chen JS.
    Acta Pharmacol Sin; 2009 Sep 15; 30(9):1316-22. PubMed ID: 19684609
    [Abstract] [Full Text] [Related]

  • 11. Peroxisome proliferator-activated receptor-gamma inhibits transformed growth of non-small cell lung cancer cells through selective suppression of Snail.
    Choudhary R, Li H, Winn RA, Sorenson AL, Weiser-Evans MC, Nemenoff RA.
    Neoplasia; 2010 Mar 15; 12(3):224-34. PubMed ID: 20234816
    [Abstract] [Full Text] [Related]

  • 12. The insulin receptor: a new anticancer target for peroxisome proliferator-activated receptor-gamma (PPARgamma) and thiazolidinedione-PPARgamma agonists.
    Costa V, Foti D, Paonessa F, Chiefari E, Palaia L, Brunetti G, Gulletta E, Fusco A, Brunetti A.
    Endocr Relat Cancer; 2008 Mar 15; 15(1):325-35. PubMed ID: 18310298
    [Abstract] [Full Text] [Related]

  • 13. Suppression of pancreatic carcinoma growth by activating peroxisome proliferator-activated receptor gamma involves angiogenesis inhibition.
    Dong YW, Wang XP, Wu K.
    World J Gastroenterol; 2009 Jan 28; 15(4):441-8. PubMed ID: 19152448
    [Abstract] [Full Text] [Related]

  • 14. Overexpression of Jab1 in hepatocellular carcinoma and its inhibition by peroxisome proliferator-activated receptor{gamma} ligands in vitro and in vivo.
    Hsu MC, Huang CC, Chang HC, Hu TH, Hung WC.
    Clin Cancer Res; 2008 Jul 01; 14(13):4045-52. PubMed ID: 18593980
    [Abstract] [Full Text] [Related]

  • 15. Peroxisome Proliferator-Activated Receptor γ Expression Is Inversely Associated with Macroscopic Vascular Invasion in Human Hepatocellular Carcinoma.
    Hsu HT, Sung MT, Lee CC, Kuo YJ, Chi CW, Lee HC, Hsia CY.
    Int J Mol Sci; 2016 Jul 29; 17(8):. PubMed ID: 27483249
    [Abstract] [Full Text] [Related]

  • 16. Peroxisome proliferator-activated receptor-γ activation inhibits hepatocellular carcinoma cell invasion by upregulating plasminogen activator inhibitor-1.
    Pang X, Wei Y, Zhang Y, Zhang M, Lu Y, Shen P.
    Cancer Sci; 2013 Jun 29; 104(6):672-80. PubMed ID: 23461356
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of oxidative stress-elicited AKT activation facilitates PPARγ agonist-mediated inhibition of stem cell character and tumor growth of liver cancer cells.
    Liu L, Yang Z, Xu Y, Li J, Xu D, Zhang L, Sun J, Xia S, Zou F, Liu Y.
    PLoS One; 2013 Jun 29; 8(8):e73038. PubMed ID: 24023668
    [Abstract] [Full Text] [Related]

  • 18. Rosiglitazone enhances 5-fluorouracil-induced cell growth inhibition in hepatocellular carcinoma cell line Hep3B.
    Cao LQ, Shao ZL, Peng HP, Xiao JB, Xia T.
    Chin J Cancer; 2010 Aug 29; 29(8):741-6. PubMed ID: 20663321
    [Abstract] [Full Text] [Related]

  • 19. Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo.
    Yu J, Qiao L, Zimmermann L, Ebert MP, Zhang H, Lin W, Röcken C, Malfertheiner P, Farrell GC.
    Hepatology; 2006 Jan 29; 43(1):134-43. PubMed ID: 16374840
    [Abstract] [Full Text] [Related]

  • 20. The farnesoid X receptor regulates adipocyte differentiation and function by promoting peroxisome proliferator-activated receptor-gamma and interfering with the Wnt/beta-catenin pathways.
    Abdelkarim M, Caron S, Duhem C, Prawitt J, Dumont J, Lucas A, Bouchaert E, Briand O, Brozek J, Kuipers F, Fievet C, Cariou B, Staels B.
    J Biol Chem; 2010 Nov 19; 285(47):36759-67. PubMed ID: 20851881
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.